Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon Luber

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Statistics in Medicine|April 15, 2016
Group sequential designs with prospectively planned rules for subpopulation enrichmentMichael Rosenblum, Brandon Luber, Richard E Thompson, et al.
The Prostate|August 17, 2016
Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective StudyBenjamin L Maughan, Brandon Luber, Rosa Nadal, et al.
Scientific Reports|March 19, 2020
Risk Factors for Progression of Barrett's Esophagus to High Grade Dysplasia and Esophageal AdenocarcinomaSwetha Kambhampati Thiruvengadam, Alan H Tieu, Brandon Luber, et al.
The Prostate|July 24, 2014
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abirateroneDaniel L Suzman, Brandon Luber, Michael T Schweizer, et al.
Cardiovascular and Interventional Radiology|November 12, 2016
Predicting Outcomes After Chemo-Embolization in Patients with Advanced-Stage Hepatocellular Carcinoma: An Evaluation of Different Radiologic Response CriteriaAndrew J Gunn, Rahul A Sheth, Brandon Luber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2017
Quantitation of Cancer Treatment Response by <sup>18</sup>F-FDG PET/CT: Multicenter Assessment of Measurement VariabilityJoo Hyun O, Heather Jacene, Brandon Luber, et al.
European Urology|February 15, 2018
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
JAMA Oncology|July 17, 2015
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate CancerEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
The Prostate|June 25, 2016
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN StudyMichael T Schweizer, Hao Wang, Brandon Luber, et al.
Cancer Chemotherapy and Pharmacology|November 10, 2016
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancerBenjamin L Maughan, Daniel L Suzman, Brandon Luber, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Statistics in Medicine|April 15, 2016
Group sequential designs with prospectively planned rules for subpopulation enrichmentMichael Rosenblum, Brandon Luber, Richard E Thompson, et al.
The Prostate|August 17, 2016
Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective StudyBenjamin L Maughan, Brandon Luber, Rosa Nadal, et al.
Scientific Reports|March 19, 2020
Risk Factors for Progression of Barrett's Esophagus to High Grade Dysplasia and Esophageal AdenocarcinomaSwetha Kambhampati Thiruvengadam, Alan H Tieu, Brandon Luber, et al.
The Prostate|July 24, 2014
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abirateroneDaniel L Suzman, Brandon Luber, Michael T Schweizer, et al.
Cardiovascular and Interventional Radiology|November 12, 2016
Predicting Outcomes After Chemo-Embolization in Patients with Advanced-Stage Hepatocellular Carcinoma: An Evaluation of Different Radiologic Response CriteriaAndrew J Gunn, Rahul A Sheth, Brandon Luber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2017
Quantitation of Cancer Treatment Response by <sup>18</sup>F-FDG PET/CT: Multicenter Assessment of Measurement VariabilityJoo Hyun O, Heather Jacene, Brandon Luber, et al.
European Urology|February 15, 2018
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
JAMA Oncology|July 17, 2015
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate CancerEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
The Prostate|June 25, 2016
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN StudyMichael T Schweizer, Hao Wang, Brandon Luber, et al.
Cancer Chemotherapy and Pharmacology|November 10, 2016
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancerBenjamin L Maughan, Daniel L Suzman, Brandon Luber, et al.
Pageof 3